The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The company operates a chain of mid-sized multi-speciality hospitals
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
This launch is part of the company's strategy to expand its nutraceutical portfolio
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
Subscribe To Our Newsletter & Stay Updated
